Next Article in Journal
A Mechanism-Based Model for the Prediction of the Metabolic Sites of Steroids Mediated by Cytochrome P450 3A4
Next Article in Special Issue
Stepchild or Prodigy? Neuroprotection in Multiple Sclerosis (MS) Research
Previous Article in Journal
Echinacoside Induces Apoptosis in Human SW480 Colorectal Cancer Cells by Induction of Oxidative DNA Damages
Previous Article in Special Issue
Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessCase Report
Int. J. Mol. Sci. 2015, 16(7), 14669-14676; doi:10.3390/ijms160714669

Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases

1
Department of Neurology, University of Ulm, Ulm 89081, Germany
2
Neuropoint Patient Academy, Neurological Practice Center, Ulm 89073, Germany
3
Department of Neurology, Military Hospital, Ulm 89081, Germany
4
Department of Neurology, Klinikum Augsburg, Augsburg 86156, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Christoph Kleinschnitz
Received: 4 June 2015 / Revised: 4 June 2015 / Accepted: 24 June 2015 / Published: 29 June 2015
(This article belongs to the Special Issue Advances in Multiple Sclerosis)
View Full-Text   |   Download PDF [636 KB, uploaded 29 June 2015]

Abstract

Alemtuzumab, a humanized monoclonal antibody targeting the surface molecule CD52, leads to a rapid depletion of immune cells in the innate and adaptive immune system. In phase 2 and 3 trials in multiple sclerosis (MS), infections have been reported more frequently in alemtuzumab than in interferon beta treated patients. Here we report two patients treated with alemtuzumab for MS developing Listeria meningitis few days after the first infusion cycle. Both patients recovered completely after prompt diagnosis and adequate treatment. Physicians and patients should be aware of this serious, but treatable complication. View Full-Text
Keywords: alemtuzumab; multiple sclerosis; Listeria monocytogenes; meningitis alemtuzumab; multiple sclerosis; Listeria monocytogenes; meningitis
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Rau, D.; Lang, M.; Harth, A.; Naumann, M.; Weber, F.; Tumani, H.; Bayas, A. Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases. Int. J. Mol. Sci. 2015, 16, 14669-14676.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top